Singular Genomics Systems Gross Profit

The latest gross profit for OMIC is $-3.1M as of September 2024. That compares with $-130K in the prior-year period — down 2361.6% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Singular Genomics Systems's historical trend and sector peers before judging valuation or financial health.

Over the past year, OMIC's gross profit moved from $-130K to $-3.1M — a 2361.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Singular Genomics Systems's operating scale or balance-sheet position.

Against Healthcare companies, OMIC currently prints $-3.1M for gross profit, while the sector average sits near $65B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Singular Genomics Systems's growth, margins, and balance sheet.

A gross profit figure of $-3.1M for OMIC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting OMIC's gross profit ($-3.1M), review year-over-year change from $-130K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.